ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clin... ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 337 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 373 | 1.0E-6 | CS |
| 26 | -9.0E-6 | -90 | 1.0E-5 | 1.0E-5 | 1.0E-6 | 1788 | 1.0E-6 | CS |
| 52 | -0.000499 | -99.8 | 0.0005 | 0.0005 | 1.0E-6 | 13962 | 9.719E-5 | CS |
| 156 | -0.044999 | -99.9977777778 | 0.045 | 0.14 | 1.0E-6 | 22827 | 0.02083712 | CS |
| 260 | -0.044999 | -99.9977777778 | 0.045 | 0.14 | 1.0E-6 | 22827 | 0.02083712 | CS |
NorthTrail
3年前
NorthTrail
3年前
NorthTrail
3年前
Invest-in-America
3年前
Invest-in-America
3年前
NorthTrail
3年前
NorthTrail
3年前
NorthTrail
3年前
tw0122
3年前
NorthTrail
3年前
Invest-in-America
3年前
NorthTrail
3年前
PennyPusher786
3年前
NorthTrail
3年前
PennyPusher786
3年前
NorthTrail
3年前
NorthTrail
3年前
Eagle909
3年前
NorthTrail
3年前
NorthTrail
3年前
Invest-in-America
3年前
Invest-in-America
3年前
Invest-in-America
3年前
madras50
3年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。